A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes

Inclusion Criteria: - Male or female, age at least 18 years at the time of signing informedconsent - Subjects fulfilling at least one of the below criteria: a) Experienced at leastone severe hypoglycaemic episode within last year (according to the ADA (American DiabetesAssociation) definition, April 2013), b) Moderate chronic renal failure, defined asglomerular filtration rate 30 - 59 mL/min/1.73 m^2 per CKD-Epi (Chronic Kidney DiseaseEpidemiology Collaboration) by central laboratory analysis, c) Hypoglycaemic symptomunawareness, d) Exposed to insulin for more than 5 years, e) Recent episode ofhypoglycaemia (defined by symptoms of hypoglycaemia and/or episode with low glucosemeasurement (below or equal to 70 mg/dL [below or equal to 3.9 mmol/L])) within the last 12weeks prior to Visit 1 (screening) - Type 2 diabetes mellitus (diagnosed clinically) for atleast 26 weeks prior to Visit 1 - Current treatment with any basal insulin (OD or BID) ±any combination of OADs (metformin, DPP-4 inhibitor, alpha-glucosidase inhibitor,thiazolidinediones, and SGLT2-inhibitor) for 26 weeks or longer prior to Visit 1 Forsubjects on BID the total daily dose should be below 75 units - HbA1c (glycosylatedhaemoglobin) below or equal to 9.5 % by central laboratory analysis - BMI (body mass index)

below or equal to 45 kg/m^2 Exclusion Criteria: - Treatment with a bolus insulin separatelyor contained in an insulin mix product within the last 26 weeks prior to Visit 1 - Use ofany other anti-diabetic agent(s) than those stated in the inclusion criteria within thelast 26 weeks prior to Visit 1